Methods One thousand and nine treatment-naïve chronic hepatitis B (CHB) patients were
evaluated for cumulative rates of virologic response, biochemical response, and entecavir …

Methods We administered 0.5 mg of entecavir once daily for more than 12 months to 114
naive chronic hepatitis B (CHB) patients. We measured the levels of liver enzymes …

OBJECTIVES: We aimed to determine the antiviral potency, viral resistance rate, and clinical
safety of 3-year continuous entecavir treatment. METHODS: We determined the cumulative …

Abstract Background and Aim Although entecavir has been shown to have good efficacy
and low resistance for the treatment of chronic hepatitis B (CHB), factors associated with a …

BACKGROUND & AIMS: We determined the antiviral potency and viral resistance rate after
4years of continuous entecavir treatment in patients with chronic hepatitis B (CHB) infection …

Background and aims. Entecavir (ETV) is effective and safe in patients with chronic hepatitis
B in the short term, but its long term efficacy and safety has not been established. Material …

There are limited data on the effects of long-term entecavir therapy in Asian patients with
chronic hepatitis B (CHB). We performed a post hoc analysis of 94 Asian hepatitis B e …

Background We determined the antiviral potency and viral breakthrough rate after 10 years
of continuous entecavir treatment in patients with chronic hepatitis B (CHB) infection …

OBJECTIVES: We aimed to determine the levels of alanine aminotransferase (ALT),
hepatitis B virus DNA (HBV DNA), HBsAg, and a novel viral marker (hepatitis B core-related …

Abstract Background and Aims The dose recommendation for entecavir (ETV) is 0.5 mg
daily for treatment-naïve chronic hepatitis B (CHB) patients and 1.0 mg daily for lamivudine …